

What makes you perfect is to be yourself.
YVOIRE® is partner for confidence.
Love yourself, YVOIRE®



References

1. Drug master file No. 17416, FDA.
2. Certification of Suitability of Monographs of the European Pharmacopoeia, R1-CEP 2004-138-REV 05, EDQM.
3. Prime Journal, 2019;9(2):73-76
4. Please request for data yvoire@lgchem.com
5. US Food and Drug Administration. Summary of Safety and Effectiveness Data. Available at : https://www.accessdata.fda.gov/cdrh_docs/pdf2/P020023b.pdf. December 12, 2003.
6. US Food and Drug Administration. Summary of Safety and Effectiveness Data. Available at : https://www.accessdata.fda.gov/cdrh_docs/pdf5/P050047b.pdf. June 2, 2006.
7. Carbohydr Polym. 2013;91(1):410-8
8. Galderma's patent, WO 2014/206701
9. Plast Reconstr Surg Glob Open 2020;8:e2648
10. ClinicalTrials.gov Identifier: NCT03738020
11. ClinicalTrials.gov Identifier: NCT03738007
12. Aesthetic Plast Surg. 2017 Apr;41(2):422-428.
13. ClinicalTrials.gov Identifier: NCT02334358
14. ClinicalTrials.gov Identifier: NCT02661737




What makes you perfect is to be yourself.
YVOIRE® is partner for confidence.
Love yourself, YVOIRE®

1. Basic Information of YVOIRE®

Product Summary

YVOIRE® provides diverse product options meeting the needs of doctors and patients.

Product		YVOIRE® classic		YVOIRE® volume		YVOIRE® contour	
		classic s	classic plus	volume s	volume plus	contour	contour plus c
Practical uses		Smoothing and Filling Fine Wrinkles		Correcting deep wrinkles & Enhancing soft tissue volume		Restoring facial volume & Defining facial contour	
Product image							
Composition	Relative particle size	Cross-linked Hyaluronic acid 		Cross-linked Hyaluronic acid 		Cross-linked Hyaluronic acid 	
	Lidocaine	-	0.3% lidocaine	-	0.3% lidocaine	-	0.3% lidocaine
Enclosed needles		30G x ½" 1ea 27G x ½" 1ea		27G x ½" 2ea		23G x 1" 1ea	23G x 1" 1ea 21G x 1½" 1ea 23G cannula x 1" 1ea
Volume per syringe		1ml	1ml	1ml	1ml	1ml	2ml

Volumizing capacity



1. Basic Information of YVOIRE®

Why choose YVOIRE®

HA* raw material manufactured according to GMP-Rules and listed in US FDA DMF.¹
Verifiable HA-Quality-Certificate of suitability to the monographs of the European Pharmacopeia by EDQM.²




* HA : Hyaluronic acid

From HA raw material to end product by LG Chem.




High elasticity and safety through HICE** Cross-linking Technology.³




** HICE : High Concentration Equalized

Proven effectiveness and safety through multiple clinical trials (More than 1,800 cumulative subjects).⁴



Sales in over 40 countries.



[As of November 2020 / The countries shown on the map may not be accurate.]

2. HA Features of YVOIRE®

Distinguishing HA raw materials

LG Chem has developed and manufactured HA products over 25 years

1990 HA R&D started with Producer Strain Development

1995 Hyal 2000 Inj., 1st HA Ophthalmic Viscoelastics developed in Korea

2005 Hyruan plus Inj., 1st 3-Injection HA Osteoarticular Viscosupplement developed in Korea

2010 YVOIRE®, 1st Cross-linked HA Filler developed in Korea

2013 YVOIRE® Plus, 1st HA Filler with Lidocaine developed in Korea



LG Chem's Hyaluronic acid products



YVOIRE®

Reliable HA raw material manufactured according to GMP-Rules and listed in US FDA DMF.¹

LG Chem's non-animal origin HA has been marketed in various medical fields since 1995 with proven safety and efficacy.




YVOIRE® uses high molecular weight HA raw material.³

YVOIRE®	3 million Daltons
Product A	1 million Daltons ⁵
Product B	2.5 million Daltons ⁶

2. HA Features of YVOIRE®

HICE Cross-linking Technology

HICE Cross-linking Technology, which enables to reach the maximum cross-linking ratio despite “minimal use of cross-linkers” by dispersing the cross-linkers into highly concentrated HA during cross-linking reaction.³



High elasticity is shown with a lower amount of cross-linker agent than those in other equivalent competing products.³


	Degree of modification ^{a)}	Elasticity ^{b)}
YVOIRE® <i>contour plus c</i>	1.9 %	497 Pa
Product A (Biphasic HA)	2.1 %	414 Pa
Product B (Monophasic HA)	7.5 %	126 Pa

a) MoD (mol%) : Expertiment and data analysis was performed according reference 7
b) Storage modulus (G', Pa) : measured at 0.02Hz (Frequency sweep mode, 25°C, strain 4%)

Efficient Cross-linking Technology

HA : Hyaluronic acid
X : Cross-linking agent


High Cross-linking Ratio means Efficient Cross-linking.⁷



$$\text{Cross-linking Ratio}^7 = \frac{N_{\text{HA-X-HA}}}{N_{\text{HA-X-HA}} + N_{\text{HA-X}}}$$

Diagram by LG Chem

Cross-linking ratio of HA filler products⁸




2. HA Features of YVOIRE®


HA particle characteristics in YVOIRE® contour, YVOIRE® contour plus c

YVOIRE® contour shows smooth surface outlines and supporting capacity owing to its ideal multi-particle size composition.⁹

In YVOIRE® contour, small particles of cross-linked HA fill the void between the large main particles, resulting in smoother gel surface on the correction areas as well as continuous, uniform and smooth injection flow regardless of its large average particle size.



Microscopic view of YVOIRE® contour



Large main particles are the core of its lifting capacity, making an outstanding lifting effect.

Small particles fill the void making the gel surface smooth.



Highlight your face shape.
YVOIRE® | *contour*



3. Clinical Data of YVOIRE®


Efficacy & Safety

YVOIRE® classic s and YVOIRE® volume s proved the clinical efficacy and safety.^{10,11}

Phase III - YVOIRE® | classic s • YVOIRE® | volume s

YVOIRE® | classic s


By measuring the mean WSRS of both groups at +26 weeks after the injection of nasolabial folds, it was demonstrated that the clinical efficacy of YVOIRE® classic s was equivalent to that of Product A(n=58).



WSRS(Wrinkle Severity Rating Scale) : A validated 5 Point Reference scale with photographs that classifies deep facial wrinkles(Grade 1 No visible folds - Grade 5 Extreme deep long folds)

YVOIRE® | volume s

By measuring the mean WSRS of both groups at +26 weeks after the injection of nasolabial folds, it was demonstrated that the clinical efficacy of YVOIRE® volume s was equivalent to that of Product A' (n=57).



3. Clinical Data of YVOIRE®

Advantage of YVOIRE® plus product

YVOIRE® plus products reduce pain during injection.¹²

Phase IV - YVOIRE® | classic plus

Objective

To compare the pain relief, efficacy, and safety of HA IDF plus (YVOIRE® classic plus) containing lidocaine with HA IDF (YVOIRE® classic s) without lidocaine during correction of nasolabial folds (NLFs).

Methods

Study design :
• A randomized, multicenter, double-blind, split-face study

Number of Subjects :
• Total 62


Investigational devices :
• Test device (YVOIRE® classic plus)
• Comparator (YVOIRE® classic s)

Evaluations :
• The first evaluation variable was the injection site pain measured using the 100-mm VAS (Visual Analogue Scale).
• The second evaluation variable included the GAIS (Global Aesthetic Improvement Scale)[†] & WSRS (Wrinkle Severity Rating Scale)[‡], and adverse events.

[†] very much improved (3), much improved (2), improved (1), no change (0), worse (-1)
[‡] extreme (5), severe (4), moderate (3), mild (2), absent (1)


Results

• YVOIRE® classic plus significantly reduced the injection-related pain.



The VAS difference between the two sides remained statistically significant throughout 60 min after the injection. Error bar means 95% Confidence Interval. Diagram by LG Chem based on data derived from the study

• The addition of lidocaine did not affect the efficacy of YVOIRE® classic plus compared with YVOIRE® classic s



Error bar means 95% Confidence Interval. Diagram by LG Chem based on data derived from the study

3. Clinical Data of YVOIRE®


Long-term Efficacy of YVOIRE®

YVOIRE® contour proved the clinical efficacy and safety of volume augmentation in mid-face for up to 1 year.⁹


Phase IV - YVOIRE® | *contour*

A multicenter, randomized, rater-blinded, active-controlled, Split-Face Design clinical study to evaluate the efficacy and safety of YVOIRE® contour (test device) compared with Product A* (biphasic HA, control device) injected into the anteromedial malar region (n=83).

MFAS score




MFAS responder rates



MFAS responder rate : percentage of the subjects with improvement in MFAS score by at least 1 grade from baseline

GAIS responder rates



GAIS responder rate : percentage of the subjects with improvement in GAIS score by at least 1 grade from baseline

MFAS(Mid Face Aesthetic Scale) : A validated 5 Point Reference scale with photographs that classifies the fullness and volume in the mid-face area(0 : Full volume ~ 4 : Very severely sunken)

GAIS (Global Aesthetic Improvement Scale) : A measure of the relative overall improvement after HA filler injection compared to the pre-injection. (-1 : Worse ~ 3 : Very much improved)

Long-term Safety of YVOIRE®

YVOIRE® classic s and YVOIRE® volume s proved the long term safety and biodegradability.^{13,14}

Phase IV - YVOIRE® | *classic s*

A multi-center, prospective and observational study to evaluate long-term safety and biodegradability of YVOIRE® classic s for 24 months after the initial injection into nasolabial folds.

- Target population : Chinese subjects whose WSRS grade is equal or greater than 2
- No. of subject : Total 503
- All the serious adverse events(1.99%) were unrelated to the investigational medical device.

The complete biodegradation was observed in all the subjects within 78 weeks after last treatment.

Phase IV - YVOIRE® | *volume s*

A multi-center, prospective and observational study to evaluate long-term safety and biodegradability of YVOIRE® volume s for 24 months after the initial injection into nasolabial fold.

- Target population : Chinese subjects whose WSRS grade is equal or greater than 2
- No. of subject : Total 503
- All of the serious adverse events(3.98%) are unrelated with the study device.
- The complete biodegradation was observed in all the subjects within 78 weeks after last treatment.

AE: adverse events

4. Injection Area of YVOIRE®

YVOIRE® | classic s
YVOIRE® | classic plus

Glabella Line
Tear Trough
Crow's feet
Barcode Lines
Upper Eyelid



YVOIRE® | volume s
YVOIRE® | volume plus

Forehead Augmentation
Lip Contouring
Lip Augmentation
Cheek
Nasolabial folds
Temple
Nose Augmentation
Marionette Line



YVOIRE® | contour
YVOIRE® | contour plus c

Cheekbones
Chin Augmentation
Jaw Line




These are for your information only, the injection areas and the appropriate products for it must be chosen according to the judgment of a trained physican.



5. Worldwide presence of YVOIRE®

YVOIRE® is being sold worldwide to over 40 countries.

[As of November 2020 / The countries shown on the map may not be accurate.]



LOVE
YOURSELF
YVOIRE

LG Chem LG aesthetics

6. Love Yourself, YVOIRE®

What makes you perfect is to be yourself. YVOIRE® is partner for confidence.



NATURALLY

Being yourself is enough to be perfect.



CLASSY

What you have becomes who you are.



SEXY

Be the one who stands out.

